Toxoplasma gondii GRA6 and ROP2A antigen mRNA-LNP vaccine and application thereof

Through the modified mRNA-LNP vaccine that binds to lipid nanoparticles of Toxoplasma GRA6 and ROP2A antigens, the existing vaccines have solved the shortcomings in immune protection and safety, and achieved efficient immune protection and safety improvement for Toxoplasma gondii , especially in the chronic infection stage, the control effect is significant.

CN118910097APending Publication Date: 2024-11-08SHANGHAI VETERINARY RESEARCH INSTITUTE CAAS (CHINESE ANIMAL HEALTH & EPIDEMIOLOGY CENTER SHANGHAI BRANCH)
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202411024050.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-29
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The existing Toxoplasma gondii vaccines have shortcomings in terms of immune protection and safety, especially in the control of chronic infection stages, and are cost-effective. Traditional vaccines such as DNA vaccines and protein vaccines have poor immunogenicity. Because mRNA vaccines are easily degraded by ribonucleases, they are difficult to be effectively delivered to cells.

Method used

The mRNA-LNP vaccine was prepared using the modified Toxoplasma GRA6 and ROP2A antigen-binding lipid nanoparticles (LNPs). By optimizing the antigen sequence and structure, LNP composed of specific lipids is used as a delivery vector to ensure the stable expression of mRNA in cells. and efficient delivery.

Benefits of technology

This vaccine can significantly improve the specific antibody level and spleen cell activity of mice, enhance cellular immune response, achieve a 100% immune protection rate, prolong the survival time after infection, and reduce the load of Toxoplasma gondii in mice.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118910097A_ABST
    Figure CN118910097A_ABST
Patent Text Reader

Abstract

The invention provides a toxoplasma gondii GRA6 and ROP2A antigen mRNA-LNP vaccine and application thereof, alpha subunits (ROP2A) of dense granular protein 6 (GRA6) and claviform protein 2 which are expressed in three infection stages of toxoplasma gondii are selected as target antigens, then GRA6 mRNA and ROP2A mRNA are obtained through in-vitro transcription, the LNP and mRNA-LNP vaccine is prepared, and the LNP and mRNA-LNP vaccine is used for preparing the toxoplasma gondii GRA6 and ROP2A antigen mRNA-LNP vaccine. The influence of the three toxoplasma gondii mRNA-LNP vaccines on humoral immunity and cellular immunity of mice and the immune protection capability are evaluated. Results show that the mRNA-LNP vaccine can activate humoral immunity and cellular immunity of mice and protect the mice from being invaded by toxoplasma gondii. The research provides a theoretical basis for the mRNA vaccine to prevent toxoplasmosis, and promotes the application of the mRNA vaccine in animal infectious diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the fields of immunology and biology, and in particular to a toxoplasma gondii GRA6 and ROP2A antigen mRNA-LNP vaccine and application thereof. Background Art

[0002] Toxoplasma gondii is an intracellular parasitic apicomplexan protozoan that can infect all warm-blooded animals. Toxoplasmosis is a parasitic disease caused by Toxoplasma gondii and has become prevalent worldwide. Most people with normal immunity do not have obvious symptoms after contracting toxoplasmosis; however, people with weakened immune function are more seriously infected, such as developing myocarditis, pneumonia or encephalitis; primary infection in pregnant women during pregnancy may cause congenital malformations or encephalopathy in the fetus, or even death.

[0003] In the treatment of toxoplasmosis, a combination of pyrimethamine and sulfadiazine is currently commonly used, which work synergistically through two steps of folate metabolism; there are other therapies such as combining the former with clindamycin, azithromycin or atovaquone. Although in the past decade, high-throughput screening strategies have been used to discover new chemicals, including natural products with anti-insect activity; or to repurpose or improve existing approved drugs for the treatment of toxoplasmosis. Although drugs are the main strategy for treatment, they are poorly tolerated, have serious side effects and drug resistance, and cannot fight the chronic infection stage of toxoplasmosis. Therefore, it is important and urgent to develop an effective and safe vaccine that is effective against both acute and chronic Toxoplasma infections.

[0004] The ideal Toxoplasma vaccine should have high immune protection and low toxicity. The protection rate of attenuated live vaccines is low and there is a risk of virulence reversion. Inactivated vaccines cannot induce effective anti-worm immunity. DNA vaccines have higher economic benefits, biocompatibility and stability than the first two, but poor immunogenicity. Protein vaccines have limited protective effects and high production costs. Compared with the previous vaccines, mRNA vaccines are safer and can be quickly taken up and expressed in cells. However, because mRNA is easily degraded by ribonucleases, its sequence and structure need to be optimized during design and production, and an effective delivery vector needs to be used to deliver it into the cytoplasm. Although lipid nanoparticles (LNPs) are currently the most commonly used mRNA vaccine delivery vectors, LNPs form spherical membrane vesicles with a size of about 50-500nm, self-assemble around a hydrophilic core, and mRNA is mostly wrapped in the core during delivery. Not only can mRNA be protected from nuclease degradation, but it can also assist in the delivery of mRNA into cells.

[0005] Compared with several traditional vaccines, RNA vaccines have low costs and high benefits, which are reflected in the following aspects. First, the research and development and production are fast: the sequences used for RNA vaccines can be selected from the database, and the RNA transcription and vaccine preparation process is a pure chemical reaction process, which does not require cell or other biological reactions (protein vaccines need to be expressed in prokaryotes, and DNA vaccines need to be expressed in eukaryotes). This not only saves time and money, but also reduces the introduction of impurities; after the RNA production system is established, when producing new RNA vaccines, only the sequence needs to be replaced, and the subsequent steps can remain unchanged. RNA vaccines have a small single-use dose: protein vaccines require 3 times for each mouse to immunize a total of 200μg, DNA vaccines require 20 to 100μg per mouse, and RNA vaccines only require 10-20μg / mouse. RNA vaccines can be optimized in many ways: there are many ways to optimize RNA sequences, including the selection of UTR regions at both ends and 5' cap structures, codon optimization, etc. The expression efficiency of RNA after modification and transformation is greatly improved; and the use of LNP can further improve the expression efficiency of RNA vaccines.

[0006] mRNA-LNP is currently being used more and more in the development of vaccines for human infectious diseases and tumors, but it is rarely used in veterinary vaccines, especially parasite vaccines. As a type of parasitic disease with the widest host range, Toxoplasma has not been effectively controlled for a long time. Inactivated vaccines, DNA vaccines, and protein vaccines for Toxoplasma have appeared in the literature, but they are only in the laboratory stage and have not yet been put into clinical use. The reason is not only the shortcomings of poor immunogenicity and insufficient safety, but also a very important factor that needs to be considered - cost-effectiveness. Summary of the invention

[0007] In order to solve the above problems, the present invention first provides an antigen that is protective against multiple infection stages of Toxoplasma gondii, wherein the antigens are GRA6 and ROP2A expressed in multiple stages of Toxoplasma gondii, wherein both GRA6 and ROP2A are modified with amino acid residues, wherein the nucleotide sequence of the modified GRA6 is shown in SEQ ID NO.4; the nucleotide sequence of the modified ROP2A is shown in SEQ ID NO.5;

[0008] Furthermore, the present invention provides a lipid nanoparticle, wherein the lipid nanoparticle is composed of four lipids, namely, 4-(N,N-dimethylamino)butyric acid (dimethyloleyl) methyl ester (DLin-MC3-DMA), distearoylphosphatidylcholine (DSPC), cholesterol (CHO-HP) and Peihua dimyristin 2000 (DMG-PEG2000);

[0009] Furthermore, the molar ratios of the above four materials are: 50:10:38.5:1.5 or 50:10:37.5:2.5;

[0010] Furthermore, the present invention provides a method for preparing the lipid nanoparticles, which comprises adding the above four components into anhydrous ethanol according to a certain molar ratio, with a total concentration of 8 mg / mL, and shaking for several minutes to completely dissolve them.

[0011] Further, the present invention provides a composition comprising at least one lipid nanoparticle; wherein the lipid nanoparticle encapsulates a ribonucleic acid (RNA) polynucleotide having an open reading frame encoding at least one polypeptide of interest, wherein the at least one polypeptide of interest comprises an antigen;

[0012] Preferably, the above polypeptide is GRA6 and / or ROP2A.

[0013] Furthermore, the present invention provides a use of the above composition in preparing a drug capable of inducing a cellular immune response.

[0014] Furthermore, the present invention provides a use of the above composition in the preparation of a medicament for preventing, diagnosing, treating or ameliorating a disease, disorder, abnormal condition or functional disorder in a mammalian subject.

[0015] Preferably, the drug is a drug for treating and / or preventing Toxoplasma gondii.

[0016] Preferably, the mammalian subject is selected from one or more of humans, non-human primates, companion animals, exotic species, livestock animals and food animals.

[0017] Furthermore, the present invention provides a Toxoplasma gondii vaccine, which contains the above-mentioned composition.

[0018] Beneficial Effects

[0019] The Toxoplasma gondii dense granule protein (GRA6) involved in the present invention is secreted by dense granules, localized in the Toxoplasma nanotube network (IVN) and the parasite vesicle membrane (PVM), and can regulate host immune-related signaling pathways and gene expression, thereby regulating the expression of cytokines. GRA6 also affects the formation of cysts, because the biogenesis of IVN requires GRA6, and IVN is essential for the development and maturation of the cyst wall and cyst membrane. Toxoplasma gondii rhoptry protein 2 (ROP2) is secreted by rhoptry bodies and is a single-copy gene. Its protein is rich in proline and arginine, and contains an N-terminal signal peptide and a C-terminal transmembrane domain. The ROP2 gene can be expressed in the tachyzoite, bradyzoite, sporozoite and other stages of Toxoplasma gondii, and induces T cell clonal proliferation to respond to Toxoplasma invasion; in addition, it can also stimulate the production of T lymphocyte-mediated cellular immune responses and related cytokines. In the process of Toxoplasma invasion of host cells, ROP2 plays a role in connecting host cells and PV.

[0020] The mRNA-LNP vaccine was further prepared with the help of the above two antigens, which can induce mice to produce specific antibodies. The antibody level increases with the number of immunizations, and the activity of mouse spleen cells in the vaccine immunization group is significantly higher than that in the control group, indicating that the mRNA-LNP vaccine can stimulate the proliferation of mouse spleen cells and enhance the activity of spleen cells. In addition, the levels of IL-2, IL-4, IL-5, IFN-γ and TNF-α in the immunization group are significantly higher than those in the control group, indicating that mRNA-LNP immunization can stimulate mouse spleen cells to produce cytokines and enhance cellular immune response. In addition, animal experiments have confirmed that the survival rate and survival time of mice in the three immunization groups are higher than those in the control group, and the GRA6 mRNA-LNP immunization group and the ROP2A mRNA-LNP immunization group have achieved 100% immune protection rate, indicating that the mRNA-LNP vaccine can protect mice from fatal Toxoplasma attacks and prolong the survival time of mice after infection with Toxoplasma. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1 PCR amplification results of GRA6 and ROP2A, including: (a) GRA6 gene PCR amplification product. (b) ROP2A gene PCR amplification product. M: DL2000 DNA Marker;

[0022] Figure 2 PCR amplification results of the modified GRA6 and ROP2A, where M: DL2000 DNA Marker. (a) PCR amplification product of GRA6 (HIS) gene. (b) PCR amplification product of ROP2A (HIS) gene.

[0023] Figure 3 Schematic diagram of mRNA in vitro transcription and expression;

[0024] Figure 4 Denaturing electrophoresis of GRA6 mRNA and ROP2A mRNA, where M: DL2000 DNA Marker. (a) GRA6 mRNA. (b) ROP2A mRNA;

[0025] Figure 5 Fluc mRNA in vitro expression of firefly luciferase activity detection, where 1: untransfected 24h blank control group cells; 2: cells transfected with uncapped Fluc mRNA 24h; 3: cells transfected with capped Fluc mRNA 24h; 4: untransfected 48h blank control group cells; 5: cells transfected with uncapped Fluc mRNA 48h; 6: cells transfected with uncapped Fluc mRNA 48h;

[0026] Figure 6 WB verified the in vitro expression of GRA6 mRNA and ROP2A mRNA, where M: protein marker. (a) In vitro expression of GRA6 mRNA. (b) In vitro expression of ROP2A mRNA.

[0027] Figure 7 Scheme 1. Physicochemical properties of mRNA-LNPs, including (a) particle size and polydispersity coefficient. (b) zeta potential.

[0028] Figure 8 Scheme 2 Physicochemical properties of mRNA-LNPs, including (a) particle size and polydispersity coefficient. (b) Zeta potential;

[0029] Fig. 9 Fluc mRNA-LNP in vitro expression of firefly luciferase activity detection, where B: untransfected 24h blank control group cells; 1: cells transfected with Fluc mRNA-LNP prepared by scheme 1 24h; 2: cells transfected with Fluc mRNA-LNP prepared by scheme 2 24h;

[0030] Fig.10 ELISA was used to detect the level of GRA6-specific antibodies, including: (a) GRA6 antibody level after the first immunization. (b) GRA6 antibody level after the second immunization. (c) GRA6 antibody level after the third immunization. (d) GRA6 antibody level after the fourth immunization.

[0031] Fig.11ELISA was used to detect the level of ROP2A specific antibodies, including: (a) ROP2A antibody level after the first immunization. (b) ROP2A antibody level after the second immunization. (c) ROP2A antibody level after the third immunization. (d) ROP2A antibody level after the fourth immunization.

[0032] Fig.12 CBA was used to detect the cytokine levels of mice in each group, including (a) mouse TNF-α level. (b) mouse IL-2 level. (c) mouse IL-5 level. (d) mouse IL-4 level. (e) mouse IFN-γ level.

[0033] Fig.13 qPCR detection of Toxoplasma load rate in various mouse tissues, including: (a) Toxoplasma load rate in mouse heart. (b) Toxoplasma load rate in mouse brain tissue. (c) Toxoplasma load rate in mouse muscle. (d) Toxoplasma load rate in mouse blood.

[0034] Fig.14 Survival rate of mice one month after immunization. DETAILED DESCRIPTION

[0035] The mice used in the experiment were 4-6 weeks old female Balb / c mice purchased from Shanghai Jiesijie Laboratory Animal Co., Ltd. and raised in the SPF-level laboratory animal center of our institute. The experimental parasite strain was the PLK strain of Toxoplasma gondii, which was cryopreserved by the Biological Vector Control Team of the Shanghai Veterinary Research Institute of the Chinese Academy of Agricultural Sciences. Vero cells and 293T cells were stored in liquid nitrogen in our laboratory. All animals were reviewed and approved by the Laboratory Animal Welfare and Ethics Committee of the Chinese Academy of Agricultural Sciences.

[0036] PrimeSTAR Max Premix(2×), pMD19-T vector, Cloning Kit for mRNA Template, Xfect TMRNA Transfection Reagent and Premix Ex Taq (Probe qPCR) were purchased from Takara; DMEM basic medium, 1640basic medium, FBS, Pen strep double antibody, and trypsin were purchased from Gibco; DH5α, BL21 competent cells, Genomic DNA Kit, gel recovery kit, plasmid extraction kit, endotoxin-free plasmid mini-preparation kit, red blood cell lysis buffer, and soluble single-component TMB substrate solution were purchased from Tiangen Biochemical Technology Co., Ltd.; DLin-MC3-DMA, DSPC, CHO-HP, and DMG-PEG2000 were purchased from Avituo (Shanghai) Pharmaceutical Technology Co., Ltd.; competent cells Fast-T1, luciferase detection kit, and CCK-8 were purchased from Novizan Biotechnology Co., Ltd.; HiScribe TM T7 mRNA Kit with Reagent and endonuclease were purchased from NEB; citrate-phosphate buffer was purchased from Macklin; (CBA) Mouse Th1 / Th2 Cytokine Kit was purchased from BD Company, USA; ConA was purchased from Sigma.

[0037] Nucleic acid electrophoresis instrument Mupid-one (Takara); protein electrophoresis instrument, semi-dry transfer instrument (Bio-rad); ultra-micro-volume spectrophotometer NanoDrop 2000, cell culture incubator HERAcell 240i (Thermo); protein stainer eStain L1 (Nanjing GenScript Biotechnology Co., Ltd.); desktop refrigerated centrifuge Centrifuge 5810R (eppendorf); nucleic acid electrophoresis instrument Mupid-one (Takara); PCR instrument (Applied Biosystems); microfluidic LNP preparation instrument (Nazhida (Shanghai) Nanotechnology Co., Ltd.); cryo-grinder (Zhejiang Meibi Instrument Co., Ltd.); flow cytometer CytoFLEX (Beckman, USA); QuantStudio5 real-time fluorescence PCR instrument (ABI); SpectraMax M5 microplate reader (Molecular Devices); plate washer (Biotek).

[0038] Example 1 Amplification and in vitro transcription of GRA6 and ROP2A

[0039] Amplification and modification of GRA6 and ROP2A

[0040] According to the Toxoplasma genome data published by the NCBI database, the GRA6 and ROP2A gene sequences were analyzed, and the primer sequences were designed as shown in Table 1. Using Toxoplasma genomic DNA as a template, the gene was amplified by PCR. The reaction system was 2 μL template, 1 μL upstream primer, 1 μL downstream primer, 25 μL PrimeSTAR Max Premix (2×), 1 μL dd2H2O2, and a total volume of 50 μL. The PCR reaction procedure was 98°C pre-denaturation for 3 min; 98°C denaturation for 10 sec, 55°C annealing for 5 sec, and 72°C extension for 10 sec, for a total of 35 cycles; 72°C extension for 5 min. After the reaction, nucleic acid electrophoresis was performed on 1% agarose to identify the product, and then the target product was recovered. The length of the GRA6 gene is 675 bp ( Figure 1 a), the nucleotide sequence of which is shown in SEQ ID NO.1, and the length of the ROP2A gene is 1729 bp ( Figure 1 b), the nucleotide sequence of which is shown in SEQ ID NO.2. The results of agarose gel electrophoresis showed that the sizes of the two gene bands were consistent with expectations. After adding an "A" tail to the 3' end of the amplified GRA6 and ROP2A genes, they were ligated into the pMD19-T vector, respectively, to obtain pMD19-T-GRA6 and pMD19-T-ROP2A plasmids.

[0041] Table 1 Primer sequences for amplification of GRA6 and ROP2A genes

[0042]

[0043] The above-mentioned fragments with correct sequencing need to be further modified after amplification using conventional biological methods to improve their expression levels in cells. For the GRA6 gene, this experiment selected its complete conserved domain (CDS) sequence; for the ROP2A gene, it is necessary to remove the redundant part of the previously amplified sequence, retain most of its CDS sequence, and optimize the codons of the remaining part. Add a His-tag sequence (CATCATCACCATCACCAT) to the rear end of each of the two genes. In the subsequent WB experiment, a commercial His-tag monoclonal antibody can be used as the primary antibody to detect the target protein expressed by mRNA in cells, which saves the preparation of polyclonal antibodies and greatly facilitates the detection of mRNA expression in vitro. Note that the starting segments of both genes must contain a start codon and the end contains a stop codon. In order to allow the template vector to be reused, EcoRI restriction sites are added before the start codon and after the stop codon of the two genes. The template used to amplify GRA6 (HIS) is pMD19-T-GRA6. Since the ROP2A sequence had modified codons, Huajin Biotechnology was commissioned to synthesize the modified ROP2A CDS fragment (shown in SEQ ID NO.3), and the synthesized fragment was used as a template to amplify the ROP2A (HIS) gene. The reaction system and conditions were the same as above, and the primer sequences were shown in Table 2. The results showed that the length of the modified GRA6 (HIS) gene was 735 bp ( Figure 2 a) (shown in SEQ ID NO.4), the length of the ROP2A (HIS) gene is 1041 bp ( Figure 2 b) (shown in SEQ ID NO.5), which was verified to be correct by sequencing.

[0044] Table 2 Primer sequence of template plasmid construction

[0045]

[0046] Transformation of template plasmid for in vitro transcription

[0047] The mRNA in vitro transcription system is mainly composed of Figure 3 The three parts shown are: construction of template plasmid, in vitro transcription of mRNA and in vitro expression verification of mRNA. In this study, firefly luciferase (Fluc) was selected as the reporter gene because its sequence is clear and its expression is stable, its expression level can be quantitatively detected using luciferase substrate, and the transcription kit used in this study contains a ready-made Fluc DNA fragment.

[0048] The template plasmid was constructed by homologous recombination method, and the reaction system was:

[0049] 1 μL of linearized vector (the linearized vector used here is a commercial vector from TaKaRa (Cat. #6143), named template plasmid for in vitro transcription (IVT) in the manual, so IVT is used to refer to this vector in the following text), 1 μL of target gene with homology arms, 6 μL of RNase Free H2O, and 2 μL of In-Fusion Enzyme Premix (5×); the reaction conditions are 50°C for 15 min.

[0050] Among them, the target gene with homology arms specifically refers to: constructing the Fluc in vitro transcription template plasmid (IVT-Fluc), the fragment used is the Fluc Control Fragment in the vector kit (TaKaRa, Cat.#6143). Constructing the GRA6 in vitro transcription template plasmid (IVT-GRA6), the fragment used is the GRA6 fragment with homology arms obtained after amplification with primers in Table 2. Constructing the GRA6 in vitro transcription template plasmid (IVT-GRA6), the fragment used is the modified GRA6 (HIS) fragment with homology arms obtained after amplification with primers in Table 2. Constructing the ROP2A in vitro transcription template plasmid (IVT-ROP2A), the fragment used is the modified ROP2A (HIS) fragment with homology arms obtained after amplification with primers in Table 2.

[0051] The recombinant template plasmid was transformed into the competent cell Fast-T1, then spread on the kanamycin resistant plate and cultured overnight. On the second day, a monoclonal colony was picked for amplification and culture, and then sent to Shanghai Sangon Biotech Co., Ltd. for sequencing. The template plasmids with GRA6 or ROP2A and their blank pathogenicity that matched the reference sequence were named IVT-Fluc, IVT-GRA6, and IVT-ROP2A, respectively. The above bacterial solution was cultured overnight, 15 mL was centrifuged at 12000 rpm for 1 min, the supernatant was removed, and the plasmid was extracted using an endotoxin-free plasmid extraction kit, and finally eluted with 120 μL of TB buffer. The concentration was measured using NanoDrop to make the plasmid concentration greater than 300 ng / μL for subsequent experiments.

[0052] Hind III restriction endonuclease was used for digestion. The reaction system was 25 μg of template plasmid IVT-Fluc / IVT-GRA6 / IVT-ROP2A, 10 μL of Buffer (10×), 5 μL of Hind III endonuclease, and 100 μL of RNase Free H2O added to the total system; the reaction conditions were 37°C for 3 hours in a water bath. The linearized template plasmid was recovered by ethanol precipitation, and finally the precipitate was dissolved with RNase Free H2O, and its concentration was measured with a NanoDrop spectrophotometer, and the concentration was adjusted to 0.5-1.0 μg / μL for subsequent experiments.

[0053] The one-step co-transcriptional capping method was selected for in vitro transcription. Specifically, the HiScribe TM T7mRNA Kit with Reagent AG was used for in vitro co-transcription capping. The templates used were the GRA6 and ROP2A template plasmids IVT-Fluc / IVT-GRA6 / IVT-ROP2A linearized in the previous step, respectively. The system was Buffer (10X) 2μL, ATP (60mM) 2μL, GTP (50mM) 2μL, UTP (50mM) 2μL, CTP (50mM) 2μL, Cap Analog (40mM) 2μL, Template DNA 1μg, DTT 1μL, T7 RNA Polymerase Mix 2μL, and Nuclease-free H2O was added to a total system of 20μL. T7 RNA polymerase should be kept on ice during preparation, and other reagents should be completely thawed at room temperature. After the system is prepared, mix well and incubate in a PCR instrument at 37℃ for 2h. In order to remove impure DNA, add 2 μL DNaseI to the post-transcription system, mix well and put it into the PCR instrument for incubation at 37°C for 15 min.

[0054] The mRNA obtained after transcription was purified and recovered by LiCl precipitation method. First, 28 μL Nuclease-free H2O was added to the post-transcription system, and then 25 μL LiCl solution was added. The mixture was gently blown and mixed, and the mixture was placed in a -30°C refrigerator for 1 hour. After centrifugation at 12000 rpm and 4°C for 15 minutes, a tiny white precipitate was visible at the bottom of the tube. The supernatant should be carefully removed at this time. 500 μL 70% ethanol (pre-cooled at 4°C) was added, and the mixture was centrifuged at 12000 rpm and 4°C for 10 minutes. The supernatant was carefully removed, and the residual ethanol was dried by opening the lid. The precipitate was resuspended in 100 μL Nuclease-free H2O, and its concentration was measured and stored in a -80°C refrigerator. 1 μL of purified mRNA was taken, 4 μL enzyme-free water was added, and the mixture was mixed and placed in a 65°C water bath for 5 minutes. The post-transcription product was detected by agarose gel electrophoresis. The electrophoresis results showed that the sizes of the two gene bands were consistent with expectations ( Figure 4 ).

[0055] At the same time, the same method as above was used to prepare uncapped Fluc mRNA (uncapFluc mRNA) and co-transcribed capped Fluc mRNA using IVT-Fluc plasmid, and 293T cells were transfected respectively. Cells were collected 24h and 48h after transfection to detect their luciferase activity. The specific steps are: the culture medium in the well plate was aspirated, 200μL of 1×CellLysis Buffer was added to each well, incubated for 8min, and the lysate was aspirated into a 1.5ml centrifuge tube after being blown evenly; centrifuged at room temperature for 2min at 11200r / min (12000g); after balancing the luciferase substrate to room temperature, 100μL was added to each well of the ELISA plate, and then 20μL of cell lysate supernatant was added to each well, and then the OD450nm of the ELISA reader was immediately read. The results showed that the luciferase activity of the control group and cells transfected with uncapped Fluc mRNA was very low, while the activity of cells transfected with capped Fluc mRNA was very high; this indicated that the expression level of uncapped Fluc mRNA in cells was very low, while the expression level of capped Fluc mRNA was stable and high, and the expression level at 24h after transfection was higher than that at 48h ( Figure 5 ).

[0056] Using a similar method as above, Takara Biotech's Xfect TMRNA Transfection Reagent was used to transfect GRA6 mRNA and ROP2A mRNA into 293T cells that had grown to about 70% adherence. 293T cells were collected 24h and 48h after transfection, and WB was used to detect whether the corresponding target proteins were expressed. The primary antibody used in WB was a commercial His-tag monoclonal antibody, and the secondary antibody used was goat anti-mouse serum. The specific steps are as follows: after ultrasonic lysis of the cell sample, add an equal amount of loading buffer to each sample tube and heat at 100°C for 10 minutes; take 20 μL of each sample and add it to the 12% precast gel loading hole, set the electrophoresis conditions to 140V, 1h; put filter paper, PVDF membrane (pre-soaked with methanol for 15s), PAGE gel after electrophoresis, and filter paper into the transfer instrument in turn, and exhaust bubbles after each layer, set the transfer conditions to 25V, 1A, 20min; put the membrane in 5% skim milk and block at room temperature for 2h; wash the membrane 3 times with TBST, 5min each time; add diluted His-tag monoclonal antibody (3% BSA diluted 100 times) and incubate at 4°C overnight; wash the membrane 3 times with TBST, 5min each time; add goat anti-mouse serum (5% skim milk diluted 5000 times) and incubate at room temperature for 2h; wash the membrane 4 times with TBST, 5min each time; prepare ultrasensitive ECL colorimetric solution and color image. The results showed that the expressed GRA6 protein should be around 25 kDa. The band in the figure moved up, and there were multiple bands at 20 kDa ( Figure 6 a); To confirm whether the upward band is GRA6 protein, this band was cut off and sent to mass spectrometry for identification. The expressed ROP2A should be around 49 kDa. The upper band in the figure is consistent with the expected size, and the brighter band below should be the shear band ( Figure 6 b). The suspected bands were cut off and sent to Shanghai Houji Biotechnology Co., Ltd. for protein mass spectrometry identification. The results showed that the detected bands were consistent with the GRA6 and ROP2A protein sequences, and the protein sequences obtained by mass spectrometry analysis were consistent with the protein sequences obtained after translation of the DNA sequences provided above. This proves that GRA6mRNA or ROP2A mRNA can be expressed in 293T cells cultured in vitro.

[0057] Example 2 Construction of GRA6 and ROP2A mRNA-LNP vaccines

[0058] The delivery material used for the mRNA vaccine in this study is lipid nanoparticles (LNP). LNP is composed of four lipids, namely 4-(N,N-dimethylamino) butyric acid (dimethyl oil) methyl ester (DLin-MC3-DMA), distearoylphosphatidylcholine (DSPC), cholesterol (CHO-HP) and pegylated dimyristin 2000 (DMG-PEG2000). The above materials are added to anhydrous ethanol in a certain molar ratio with a total concentration of 8 mg / mL, and shaken for several minutes to completely dissolve them. This study tested two schemes of LNP, which are marked as Scheme 1 and Scheme 2 below. The molar ratios of the four materials used in the two schemes are as follows:

[0059] Table 3 Molar ratio of each component of LNP

[0060]

[0061] The transcribed mRNA was dissolved in a citrate-phosphate buffer solution with a pH of 4.0 at a concentration of 0.1 mg / mL. This study used the microfluidic LNP preparation instrument of Nazhida (Shanghai) Nanotechnology Co., Ltd., and the microfluidic chip needed to be pre-washed with anhydrous ethanol before use. Use a Kangdeli (KDL) screw-mouth syringe to extract an appropriate amount of mRNA and LNP (the ratio of the two liquid volumes is 3:1), and then tighten the screw mouth of the syringe to the chip injection port. Set the total volume according to the extraction volume, set the mRNA and LNP flow rate ratio to 3:1, the total flow rate to 12 mL / min, set the front waste liquid to 0.1 mL and the rear waste liquid to 0.02 mL; after the settings are completed, click to start preparation.

[0062] After the preparation of mRNA-LNP is completed, 50 μL of sample is diluted 20 times with ddH2O water, and the particle size and polydispersity index (PDI) are detected, and then transferred to the potential cell to detect the ZETA potential; the prepared mRNA-LNP is diluted 10 times with 1×PBS, and then added to Milipore 30kDa ultrafiltration tube in batches, centrifuged at 3000g for 30 minutes at 4°C, and the milky white liquid obtained after filtration is the candidate mRNA-LNP vaccine.

[0063] The results of properties showed that the particle size of Fluc mRNA-LNP prepared in Scheme 1 was 96.22±0.10nm ( Figure 7 a), PDI is 0.2767±0.0079, and zeta potential is 17.66 mV ( Figure 7 b). The particle size of the Fluc mRNA-LNP prepared in Scheme 2 was 99.11±0.41nm ( Figure 8 a), PDI is 0.2573±0.0045, and zeta potential is 11.77 mV ( Figure 8b). The particle sizes of the two types of Fluc mRNA-LNP are both less than 100 nm. The particle size of Scheme 2 is larger, the PDI is smaller, and the absolute value of the ZETA potential is smaller; the smaller PDI indicates that it is more uniform, and the smaller absolute value of the ZETA potential indicates that it is more likely to aggregate.

[0064] The two Fluc mRNA-LNPs obtained after filtration were added to the twelve-well plate cultured with 293T cells (the medium was replaced with serum-free medium before addition), and the expression of luciferase was detected after 24 hours. The detection steps were the same as above. The results showed that the Fluc mRNA-LNPs prepared by the two schemes could be efficiently expressed in 293T cells cultured in vitro, and the expression level of scheme 2 was higher than that of scheme 1 ( Fig. 9 ).

[0065] Detection of mRNA-LNP vaccine-induced immune response in mice

[0066] This study set up 5 groups of experimental mice, namely PBS group, LNP group, GRA6 mRNA-LNP group, ROP2AmRNA-LNP group, and GRA6+ROP2AmRNA-LNP group. There were 10 mice in each group, and each mouse was immunized 4 times, with an interval of 2 weeks between two immunizations, and the same dose for each immunization. The injection volume for each mouse each immunization was: 100μL PBS was injected in the PBS group, 100μL LNP was injected in the LNP group, and 100μL of mRNA-LNP mixture containing 20μg mRNA was injected in the three mRNA-LNP groups. Among them, the GRA6 mRNA-LNP group was injected with 100 μL GRA6 mRNA-LNP vaccine containing 20 μg GRA6 mRNA, the ROP2A mRNA-LNP group was injected with 100 μL ROP2A mRNA-LNP vaccine containing 20 μg ROP2A mRNA, and the GRA6+ROP2A mRNA-LNP group was injected with GRA6+ROP2A mRNA-LNP vaccine containing 10 μg GRA6 and 10 μg ROP2A.

[0067] The GRA6 mRNA-LNP vaccine, ROP2A mRNA-LNP vaccine and GRA6+ROP2A mRNA-LNP vaccine used were prepared according to the molar ratio of Scheme 2 in Table 3. The GRA6 mRNA-LNP vaccine was prepared with GRA6 mRNA and LNP, the ROP2A mRNA-LNP vaccine was prepared with ROP2A mRNA and LNP, and the GRA6+ROP2A mRNA-LNP vaccine was prepared with GRA6 mRNA, ROP2A mRNA and LNP. The specific preparation method is to dissolve the transcribed mRNA in a citrate-phosphate buffer solution with a pH of 4.0 at a concentration of 0.1 mg / mL. This study uses the microfluidic LNP preparation instrument of Nazhida (Shanghai) Nanotechnology Co., Ltd., and the microfluidic chip needs to be pre-washed with anhydrous ethanol before use. Use a KDL screw-mouth syringe to extract an appropriate amount of mRNA and LNP (the ratio of the two liquid volumes is 3:1), and then tighten the screw mouth of the syringe and the chip injection port. Set the total volume according to the extracted volume, set the mRNA and The LNP flow rate ratio is 3:1, the total flow rate is 12mL / min, and the front waste liquid is set to 0.1mL and the rear waste liquid is set to 0.02mL; after the settings are completed, you can click to start preparation. After the mRNA-LNP is prepared, take 50μL of the sample and dilute it 20 times with ddH2O water, and then test the particle size and polydispersity index (PDI), and then transfer it to the potential cell to detect the ZETA potential; the prepared mRNA-LNP is diluted 10 times with 1×PBS, and then added to a 30kDa ultrafiltration tube in batches, centrifuged at 3000g for 30min at 4℃, and the milky white liquid obtained after filtration is the candidate mRNA-LNP vaccine.

[0068] Eight mice were randomly selected from each group and tail vein blood was collected two weeks after each immunization. The blood was incubated at 37°C for 4 h. After the serum was precipitated, it was centrifuged for 10 min at 5000 r / min. The serum was collected and stored at -80°C. The steps for ELISA detection of specific antibodies in the serum of mice after immunization are as follows: add 100 μL of antigen (diluted to 1 μg / mL with CBS) to each well of a 96-well plate, wrap it with plastic wrap and incubate it at 4°C overnight; wash the plate 3 times with PBST; add 100 μL of skim milk to each well for blocking, and incubate it at 37°C for 1 h; after shaking out the liquid in the plate, add 100 μL of diluted primary antiserum (diluted 100 times with 3% skim milk) to each well, and incubate it at 37°C for 1 h; shake out the liquid in the plate and wash the plate 6 times with PBST; add 100 μL of diluted goat anti-mouse serum (diluted 4000 times with 3% skim milk) to each well, and then incubate it at 37°C for 1 h; after washing the plate 6 times with PBST, add 100 μL of substrate colorimetric solution to each well, incubate at room temperature for 30 min, add 100 μL of H2SO4 (1 mol / L) stop solution to each well, and place it in an ELISA reader to read the data at 450 nm.

[0069] ELISA test results showed that the GRA6 antibody levels of mice in the GRA6 mRNA-LNP and GRA6+ROP2A mRNA-LNP immunization groups were significantly higher than those in the PBS group, LNP group, and ROP2A mRNA-LNP immunization group; and the GRA6 antibody levels of the two groups increased with the increase in the number of immunizations. The GRA6 antibody level of mice in the GRA6+ROP2A mRNA-LNP immunization group was higher than that in the GRA6 mRNA-LNP immunization group after the first three immunizations, and was lower than that in the GRA6 mRNA-LNP immunization group after the fourth immunization, and the difference between the two was not significant. This result shows that both GRA6 mRNA-LNP and GRA6+ROP2A mRNA-LNP can induce mice to produce GRA6-specific antibodies, and the antibody level increases with the increase in the number of immunizations ( Fig.10 ).

[0070] Similarly, the ROP2A antibody levels of mice in the ROP2A mRNA-LNP and GRA6+ROP2A mRNA-LNP immunization groups were significantly higher than those in the PBs group, LNP group, and GRA6 mRNA-LNP immunization group; and the ROP2A antibody levels of both groups increased with the increase in the number of immunizations. The ROP2A antibody level of mice in the GRA6+ROP2A mRNA-LNP immunization group was higher than that in the ROP2A mRNA-LNP immunization group after the third immunization, and there was no significant difference in the ROP2A antibody levels of the two groups after the first, second, and fourth immunizations. This result shows that both ROP2A mRNA-LNP and GRA6+ROP2A mRNA-LNP can induce mice to produce ROP2A-specific antibodies, and the antibody level increases with the increase in the number of immunizations ( Fig.11 ).

[0071] One week after the fourth immunization, two mice were randomly selected from each group, and the spleens were removed by dissection. The spleens were placed in a 70 μm cell sieve, and the spleens were flushed with 1640 medium containing 5% double antibody. The spleens were ground with the front end of the plunger of a 2.5 mL syringe, and then rinsed with the medium several times until no tissue was visible in the sieve holes. The liquid was collected in a centrifuge tube, centrifuged at 1000 r / min for 5 min, and then the liquid was removed; 1 mL of red blood cell lysis buffer was added and gently shaken for 1 min, and 2 mL of culture medium was added to stop; the supernatant was discarded after centrifugation at 1000 r / min for 5 min, and this step was repeated 1 to 2 times; the spleen cells were resuspended in 1640 complete medium, and the concentration was diluted to 2×10 after counting. 6 / mL, and then 100μL was added to each well of a 96-well plate; then 100μL of purified GRA6 or ROP2A protein at a concentration of 10μg / mL was added to each well for stimulation; after culturing in a cell culture incubator for 72h, IL-2, IL-4, IL-5, IFN-γ and TNF were detected using a CBA mouse cytokine detection kit. The specific steps are as follows: take out a bottle of freeze-dried standard, dissolve it with 2mL of diluent, then let it stand at room temperature for 15min, gradient dilute the standard to a minimum dilution of 1:512, and prepare another negative tube; shake and resuspend the cytokine microspheres, take out 10×NμL of each (N is the number of all samples including standards), mix them into 50×NμL of mixed microspheres, and shake them to mix them thoroughly; add 50μL of sample / standard, 50μL of mixed microspheres and 50μL of PE detection reagent to each tube, and incubate in the dark for more than 3h; debug the flow cytometer during incubation. Prepare 3 debugging tubes, namely A tube (50μL set microsphere + 450μL washing solution), B tube (50μL set microsphere + 50μL FITC positive reagent + 400μL washing solution), C tube (50μL set microsphere + 50μL PE positive reagent + 400μL washing solution); after turning on the flow cytometer, first draw a scatter plot (FSC+SSC, PE, APC), histogram (PE / FITC as the horizontal axis, APC as the vertical axis); after loading tube A, find the cell population and circle the P1 gate. Then load tubes B and C to adjust the voltage and compensation; after the sample incubation is completed, add 1mL of washing solution to each tube, centrifuge at 200g for 5min, ensure that a tiny white precipitate appears at the bottom of the tube, carefully aspirate the supernatant, and then use 300μL washing solution to resuspend the precipitate; first load the standard sample from the highest to the lowest concentration to ensure that it is within the image range; then test the samples in turn and record the data.

[0072] The results showed that the levels of TNF-α, IL-2 and IL-5 cytokines in the GRA6 mRNA-LNP immunization group were significantly higher than those in the LNP control group; the levels of IL-4 in the GRA6 mRNA-LNP and ROP2AmRNA-LNP immunization groups were significantly higher than those in the control group, and the levels of IFN-γ in the three immunization groups were higher than those in the LNP control group. In general, the cytokine levels of the three immunization groups were higher than those in the control group, indicating that mRNA-LNP immunization can stimulate the production of cytokines in mouse spleen cells and enhance cellular immune responses ( Fig.12 ).

[0073] Experimental study on mRNA-LNP vaccine to prevent Toxoplasma gondii in mice

[0074] Two weeks after the fourth immunization, the remaining mice in each group were intraperitoneally injected with 1×10 4The survival of mice in the next 30 days was recorded for the drawing of survival curves. One week after inoculation, 2 mice were randomly selected from each group and dissected in a biosafety cabinet. The heart, muscle, and brain tissues were taken and weighed. 400 μL PBS was added to every 0.1 g of tissue, and then ground at -30°C for 25 minutes. Then the same volume of each tissue was added to the fully automatic nucleic acid extractor for tissue DNA extraction; the recombinant plasmid of the 529bp repeat sequence of Toxoplasma gondii was diluted tenfold, with the highest concentration of 1ng / μL and the lowest of 10 -7 ng / μL, and a standard curve was established. At the same time, Toxoplasma PLK strain DNA was added as a positive control, and ddH2O was used as a negative control. The reaction system was: template DNA 1.25μL, upstream primer 0.5μL, downstream primer 0.5μL, probe 1μL, Premix Ex Taq (Probe qPCR) 12.5μL, ddH2O 25μL. The reaction conditions were: 95℃30s, 95℃5s, 60℃34s, for a total of 40 cycles. The reference was the Toxoplasma 529bp repetitive sequence recombinant plasmid; the name sequences of the primers and probes are as follows, P1: GCTCGCCTGTGCTTGGAG; P2: ATCTTCTCCCTCTCCGACTCTC; Probe: FAM-TCGCTTCCCAACCACGCCACCC-BHQ1. Refer to the previous work and published articles of our laboratory: Lin Z, Zhang Y, Zhang H, Zhou Y, Cao J, Zhou J. Comparison of loop-mediated isothermal amplification (LAMP) and real-time PCR method targeting a 529-bp repeat element for diagnosis of toxoplasmosis. Vet Parasitol. 2012Apr 30; 185(2-4): 296-300. The experimental data were analyzed and processed using the software Graphpad Prism. P>0.05 indicates no significant difference (ns), P<0.05 (*), P<0.01 (**), P<0.001 (***) and P<0.0001 (****) indicate significant differences. The results showed that the Toxoplasma load in various tissues of mice immunized with the three groups of mRNA-LNP vaccines was lower than that in the control group, especially the load in the heart and blood was significantly reduced ( Fig.13 ); indicating that mRNA-LNP immunization can reduce the proliferation and migration of Toxoplasma gondii in mice.

[0075] Moreover, the survival curves showed that the GRA6 mRNA-LNP immunization group and the ROP2A mRNA-LNP immunization group achieved a 100% immune protection rate, while the survival rate of mice in the GRA6+ROP2A mRNA-LNP mixed immunization group was 75%, and the survival rates of mice in the LNP control group and the PBs control group were 37.5% and 25%, respectively; the survival rates of mice in the three immunization groups were all higher than those in the control group. It can also be seen from this figure that if the survival time of the last surviving mice is counted as 30 days, the average survival time of mice in the three immunization groups is significantly higher than that in the control group, and the average survival time of mice in the GRA6 mRNA-LNP and ROP2A mRNA-LNP groups reached the highest 30 days. In summary, the survival rate and survival time of mice in the GRA6 mRNA-LNP immunization group, the ROP2A mRNA-LNP immunization group, and the GRA6+ROP2A mRNA-LNP immunization group were higher than those in the control group, indicating that mRNA-LNP can improve the survival rate of mice infected with Toxoplasma gondii and prolong the survival time after infection ( Fig.14 ).

[0076] The above results fully demonstrate that this study successfully constructed an mRNA in vitro transcription system. GRA6 and ROP2A in vitro transcription template plasmids were constructed, and GRA6 mRNA and ROP2A mRNA with His-tag sequences were successfully transcribed in vitro. The target protein was successfully expressed after GRA6 mRNA and ROP2A mRNA were transfected into 293T cells. Two Fluc mRNA-LNPs were successfully prepared, and the particle size, PDI, and ZETA potential of both were detected. The results showed that both can be used in animals. Both Fluc mRNA-LNPs can be efficiently expressed in 293T cells but at different expression levels. One of the LNPs with a higher expression level was selected for the preparation of Toxoplasma gondii mRNA-LNP vaccines with GRA6 and ROP2A antigens. mRNA-LNP vaccines can enhance the activity of mouse spleen cells and promote the secretion of cytokines. mRNA-LNP vaccines can significantly reduce the parasite load in various tissues of mice after worm attack and increase the survival rate of mice, protecting mice from Toxoplasma gondii. The GRA6 mRNA-LNP vaccine, ROP2A mRNA-LNP vaccine and GRA6+ROP2A mRNA-LNP vaccine prepared in this study can induce mice to produce corresponding specific antibodies. The antibody level increases with the number of immunizations, and these three mRNA-LNP vaccines can promote the secretion of cytokines. These three mRNA-LNP vaccines can reduce the proliferation and migration of Toxoplasma gondii in mice and increase the survival rate of mice infected with Toxoplasma gondii. Among these three vaccines, GRA6 mRNA-LNP vaccine induces stronger cellular immunity and immune protection against Toxoplasma gondii in mice.

[0077] The above description of the embodiments is to facilitate the understanding and use of the present invention by those skilled in the art. It is obvious that those skilled in the art can easily make various modifications to these embodiments and apply the general principles described herein to other embodiments without creative work. Therefore, the present invention is not limited to the above embodiments. Improvements and modifications made by those skilled in the art based on the principles of the present invention without departing from the scope of the present invention should be within the protection scope of the present invention.

Claims

1. An antigen that is protective against multiple infection stages of Toxoplasma gondii, characterized in that: The antigens are modified Toxoplasma GRA6 and ROP2A, wherein the nucleotide sequence of the modified GRA6 is shown in SEQ ID NO.4; the nucleotide sequence of the modified ROP2A is shown in SEQ ID NO.

5.

2. A lipid nanoparticle, which is composed of four lipids, namely 4-(N,N-dimethylamino)butyric acid (dimethyloleyl) methyl ester (DLin-MC3-DMA), distearoylphosphatidylcholine (DSPC), cholesterol (CHO-HP) and Pei-modified dimyristin 2000 (DMG-PEG2000).

3. A lipid nanoparticle as claimed in claim 2, wherein the molar ratio of the four materials is 50:10:38.5:1.5 or 50:10:37.5:2.

5.

4. A method for preparing the lipid nanoparticles according to claim 2 or 3, specifically: adding the above four components into anhydrous ethanol in a certain molar ratio to a total concentration of 8 mg / mL, and shaking for several minutes to completely dissolve them.

5. A composition comprising a lipid nanoparticle as described in claim 2 or 3; wherein the lipid nanoparticle encapsulates a ribonucleic acid (RNA) polynucleotide having an open reading frame encoding at least one polypeptide of interest, wherein the at least one polypeptide of interest comprises an antigen.

6. The composition of claim 5, wherein the antigen is GRA6 and / or ROP2A in claim 1.

7. Use of the composition according to claim 6 in the preparation of a medicament for preventing, diagnosing, treating or ameliorating a disease, disorder, abnormal condition or dysfunction in a mammalian subject, wherein the medicament is a medicament for treating and / or preventing Toxoplasma gondii.

8. A Toxoplasma gondii vaccine, characterized in that The vaccine contains the antigen according to claim 1 and / or the composition according to claim 6.

Citation Information

Cited By

  • In-vitro transcription system of theileria annulata transformed cells and construction method of in-vitro transcription system

    CN120700021A

  • In vitro transcription system of circular theileria-transformed cells and method for constructing the same

    CN120700021B